Narcolepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Narcolepsy is a chronic sleep disorder characterized by two major symptoms: excessive daytime sleepiness (EDS) and cataplexy. This condition is also characterized by abnormal rapid eye movement (REM) with two associated symptoms: sleep paralysis and hypnagogic hallucinations. Narcolepsy is caused by loss of orexin signaling, genetic factors, and rare brain lesions. Orexin-A and orexin-B, also known as hypocretin-1 and hypocretin-2, are neuropeptides that have an excitatory effect on the CNS. This effect results from binding to the orexin receptor 1 (OxR1) and orexin receptor 2 (OxR2) on the postsynaptic neurons.

The narcolepsy marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for narcolepsy. Moreover, it analyzes the clinical and commercial landscapes of narcolepsy, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Narcolepsy Marketed and Pipeline Drugs Overview by Mechanism of Action

The major mechanisms of action in the narcolepsy marketed and pipeline drugs market are transporter inhibitor, receptor agonist, receptor antagonist, protein & peptide inhibitor, and receptor modulator.

Narcolepsy Marketed and Pipeline Drugs Market Analysis by Mechanism of Action

For more mechanism of action insights, download a free report sample

Narcolepsy Marketed and Pipeline Drugs Overview by Routes of Administration

The major routes of administration in the narcolepsy marketed and pipeline drugs market are oral therapies, injections, and inhalational therapies.

Narcolepsy Marketed and Pipeline Drugs Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Market Report Overview

Scope

GlobalData’s Narcolepsy: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Narcolepsy market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Narcolepsy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.